What Pivotal bioVenture Partners Investment Advisor LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1844645 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 1M |
| −20.3% |
| $26.6M |
| 10.6% |
TRVITrevi Therapeutics, Inc. | 1.7M | ±0% | $25M | 9.9% |
AVLNAvalyn Pharma Inc. | 866.8K | −10.3% | $24.7M | 9.8% |
EVMNEvommune, Inc. | 1.9M | ±0% | $15.9M | 6.3% |
IMNMImmunome Inc. | 732.5K | ±0% | $15.8M | 6.3% |
OCSOculis Holding AG | 1.7M | +10.1% | $15.5M | 6.2% |
OBXObsidian Therapeutics, Inc. | 860.3K | New | $11.8M | 4.7% |
AVTXAvalo Therapeutics, Inc. | 434K | ±0% | $6.7M | 2.6% |
BRVEBraveheart Bio, Inc. | 317.4K | New | $6.4M | 2.5% |
ZBIOZenas BioPharma, Inc. | 233.2K | −52.5% | $6.3M | 2.5% |
MPLTMapLight Therapeutics, Inc. | 611.4K | ±0% | $6.2M | 2.5% |
RLYBRallybio Corp | 300.6K | ±0% | $5.2M | 2.1% |
BIOABioAge Labs, Inc. | 653.4K | ±0% | $4.6M | 1.8% |